FDA approves AstraZeneca’s Tagrisso to treat mutation-positive NSCLC
The approval has been granted to treat patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test whose disease has progressed on or after an
The US Food and Drug Administration (FDA) has declined to approve Unicycive Therapeutics’ resubmitted new drug application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.